Last reviewed · How we verify
Allegra (fexofenadine)
Fexofenadine (Allegra) is the least sedating antihistamine available, approved in 1996 as the safe successor to terfenadine. Available OTC and generically worldwide.
At a glance
| Generic name | fexofenadine |
|---|---|
| Also known as | Allegra, Telfast |
| Sponsor | Generic (originally Hoechst Marion Roussel/Sanofi) |
| Drug class | Second-generation antihistamine |
| Target | Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1996-07-25 (United States) |
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Chronic idiopathic urticaria
- Seasonal allergic rhinitis
- Sneezing
Common side effects
Key clinical trials
- The Evaluation of Efficacy and Safety of Fexofenadine 180mg Tablets for 7 Days in the Treatment of Pruritic Skin Disease (Phase 4)
- A Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Pharmacokinetics and Pharmacodynamics at Two Dose Levels of SJP-001 in Comparison With Fexofenadine and Naproxen Administered (Phase 1)
- A Relative Bioavailability Study of 180 mg Fexofenadine Hydrochloride Tablets Under Fasting Conditions. (Phase 1)
- Vascular Function in Health & Disease: Rehabilitation for Hypertension; Exercise and Skeletal Muscle Afferent Feedback (Phase 1)
- An Open Label, Balanced, Randomized, Two-way, Single Dose, Crossover Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tabs of Dr. Reddy's and Allegra-D 24 hr ER Tabs of (Phase 1)
- The Effect of Sodium Lauryl Sulfate on the Oral Absorption of Fexofenadine in Humans (EARLY/Phase 1)
- Clinical Study to Compare The Safety and Possible Efficacy of Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis (Phase 4)
- A Double-Blind, Parallel, Randomized, Placebo Controlled Trial to Evaluate Onset of Action of Loratadine and Fexofenadine in Subjects With Seasonal Allergic Rhinitis in a Pollen Challenge Chamber (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allegra CI brief — competitive landscape report
- Allegra updates RSS · CI watch RSS
- Generic (originally Hoechst Marion Roussel/Sanofi) portfolio CI